Agilent cancer treatment approved in Europe
Agilent Technologies, with offices in Carpinteria, announced a product designed to identify previously untreated non-small cell lung cancer patients with a tumor proportion score of 50 percent or more was approved for use in Europe in conjunction with Merck’s Keytruda therapy. Before using the product – called PD-L1 IHC 22C3 pharmDx and developed by Agilent Read More →
CompuVision, Sagewood announce consolidation
IT services company CompuVision announced a partnership with health care technology services company Sagewood Systems, both based in Santa Barbara, on Jan. 31. The move will consolidate the companies’ technology, management and communications offerings under the CompuVision brand, it said in a news release, including consulting, enterprise applications and a “hyperconverged infrastructure” system that combines Read More →
Amgen CEO meets with Trump, vows to add 1,600 jobs
Amgen CEO Robert Bradway met with President Donald Trump on Jan. 31 and vowed to add 1,600 jobs, Bloomberg News reported. Trump told biotech leaders at a White House meeting that drug prices needed to come down and he would find a way to streamline the regulatory process. He has discussed having the government negotiate Read More →
InTouch Health to celebrate opening of Goleta headquarters
Telehealth developer InTouch Health will celebrate the grand opening of its new corporate headquarters at 7402 Hollister Ave. in Goleta on Jan. 31. The new facility includes an advanced technology “innovation center” that showcases medical care delivery solutions via robotics and cloud-based networks. InTouch created the world’s first robotic telehealth system shortly after its founding Read More →
Europeans recommend approval of Amgen’s biosimilar of AbbVie’s Humira
The European Medicines Agency recommended the approval of the ABP 501, a biosimilar of AbbVie’s Humira (adalimumab), for treatment of inflammatory diseases, Thousand Oaks-based biotech company Amgen announced on Jan. 27. The EMA recommended ABP 501’s use for moderate-to-severe rheumatoid arthritis, psoriatic arthritis, severe ankylosing spondylitis, severe axial spondyloarthritis without radiographic evidence of AS, moderate-to-severe Read More →
Cynvenio inks deal with Milenia Labs to distribute blood test
Westlake Village cancer treatment company Cynvenio Biosystems announced an exclusive agreement with diagnostic test company Milenia Labs to distribute a blood test for breast cancer at its 12 diagnostic centers in Mexico. Financial details of the deal were not disclosed. The test provides real-time information about cancer cell activity for patients who have completed treatment Read More →
Patent ruling in favor of Amgen has shares skyrocketing
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
